Rani Therapeutics (RANI) Q4 2024 earnings summary

Executive summary

• Advanced the RaniPill platform for oral biologics, focusing on obesity and immunology, with significant pipeline progress in 2024 and early 2025.

• Strategic partnership with ProGen for RT-114, a GLP-1/GLP-2 dual agonist, to create a differentiated oral obesity therapy.

• Preclinical data for RT-114 and RT-116 (oral semaglutide) showed high bioavailability, comparable pharmacokinetics, and weight loss to subcutaneous administration.

• Announced positive topline results from Phase 1 study of oral anti-IL-12/23 antibody (RT-111) with high bioavailability and good tolerability.

• RT-114 is prioritized for clinical advancement in 2025 due to capital constraints, with other programs on hold pending additional funding.

Financial highlights

• Cash, cash equivalents, and marketable securities were $27.6M as of Dec 31, 2024, down from $48.5M a year earlier; sufficient to fund operations into Q3 2025.

• Contract revenue for 2024 was $1M, with no such revenue in 2023.

• R&D expenses for 2024 were $26.7M, down from $39.6M in 2023, reflecting cost containment and workforce reduction.

• G&A expenses for 2024 were $23.9M, down from $26.5M in 2023, primarily due to lower compensation and third-party costs.

• Net loss for 2024 was $56.6M, improved from $67.9M in 2023; Q4 net loss was $15.7M.

• Completed two equity offerings raising $20.0M in gross proceeds.

• Recorded a $3.7M impairment loss on manufacturing assets in 2024.

Outlook and guidance

• RT-114 is expected to enter clinical trials in mid-2025, with a focus on demonstrating safety, tolerability, and weight loss in obese, non-diabetic patients.

• No immediate plans to advance RT-116 (oral semaglutide) to clinic; focus remains on RT-114.

• Cash reserves expected to fund operations into Q3 2025 without additional funding.

• Additional immunology and endocrinology assets may progress as capital allows.